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Abstract
Seroepidemiology of chlamydia can offer study opportunities and insights into cumulative risk of exposure that may
contribute to monitoring the frequency of, and control of, genital chlamydia–the most commonly diagnosed STI in England.
We undertook retrospective anonymous population-based cross-sectional surveys using an indirect IgG ELISA for chlamydia
Pgp3 antibody. Sera from 4,732 women aged 17–24 years were tested. Samples were taken at 3-yearly intervals between
1993 and 2002, a period during which other data suggest chlamydia transmission may have been increasing, and from each
year between 2007 and 2010. Seroprevalence increased in 17–24 year olds over time between 1993 and 2002. Between
2007 and 2010, age-standardised seroprevalence among 17–24 year olds decreased from 20% (95% CI: 17–23) to 15%
(95%CI 12–17) (p = 0.0001). The biggest drop was among 20 to 21 year olds, where seroprevalence decreased from 21% in
2007 to 9% in 2010 (p = 0.002). These seroprevalence data reflect some known features of the epidemiology of chlamydia
infection, and show that exposure to antibody-inducing chlamydia infection has declined in recent years. This decline was
concurrent with increasing rates of screening for asymptomatic chlamydia. Serology should be explored further as a tool for
evaluation of chlamydia control, including chlamydia screening programmes.
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Introduction
Chlamydia trachomatis is the most common sexually transmitted
bacterium in the developed world, with a high prevalence of
infection [1–3]. In 2012 there were 207,000 diagnoses in England,
with the highest rates occurring in young adults [4]. Symptoms of
acute infection include painful urination, urethral or vaginal
discharge [5], but the majority of infections are asymptomatic. If
untreated, chlamydia can give rise to chronic infection and
sequelae that include pelvic inflammatory disease, chronic pelvic
pain, ectopic pregnancy and tubal factor infertility [5].
Current knowledge of the epidemiology of C. trachomatis
infection in the UK relies heavily on nucleic acid amplification
tests (NAATs) in which C. trachomatis DNA is amplified from
genital swabs or urine. These specimens tend to be available only
from sexually active women. These data provide some information
on current infection, but information on the prevalence of past
infection or the cumulative risk of infection cannot be derived from
NAAT testing, nor are the women tested truly representative of
the general population [6–9]. Until recently, investigation of
C. trachomatis seroepidemiology has been seriously hampered by
relatively poor sensitivity and specificity of serological assays
[9,10]. Most chlamydia seroprevalence assays have not been
evaluated using sera from patients unambiguously known to be
exposed or never exposed to C. trachomatis [9,11] and the older
generation assays contained C. pneumoniae homologues, a common
respiratory pathogen. As a result, chlamydia serology as a means
of understanding the natural history of infection fell out of favour
[11]. In 2009, we produced an ‘‘in-house’’ indirect immunoglob-
ulin G (IgG) enzyme-linked immunosorbent assay (ELISA) based
on the C. trachomatis-specific antigen Pgp3 and demonstrated its
potential for utilisation in seroepidemiological surveys [10]. We
evaluated this ELISA against three commercial MOMP peptide
ELISA assays, using sera from 164 women who had been infected
with C. trachomatis and from 722 chlamydia-negative children aged
2–13 years [10]. This ELISA was significantly more sensitive than
the best performing MOMP peptide ELISA (Anilabsystems)
(73.8% vs 59.8% P=0.001) (95% CI 66.5% to 79.9%) and had
a specificity of 97.6% (95% CI 96.2% to 98.6%) amongst 164
women (at least 14% better than the best assays available
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commercially [10]), with no evidence of detection of cross-reactive
C. pneumoniae antibody in a study of 722 samples from children
[10].
There are challenges to the interpretation of chlamydia
seroprevalence. Seroprevalence is likely to underestimate the
proportion of women who have had a chlamydia infection as only
68% of infected women remain antibody-positive after 6 months
[12], unless they are subsequently re-infected, and infection in the
upper genital tract is more likely to induce an antibody response
than a mucosal infection at the cervix alone [13]. There may also
be differences in the rate of antibody inducing infection depending
on factors such as whether or not there is treatment and how soon
this is given post-infection [14].
Data from surveillance of sexually transmitted infections (STIs)
diagnosed in GUM clinics in England have suggested there was a
fall in transmission of STIs in 1986–7 associated with the
campaigns for safer sex designed to prevent HIV transmission.
There were falls in rates of gonorrhoea and genital herpes and an
interruption to rises in genital warts, and an overall reduction in
new GUM clinic attendances requiring treatment (whilst atten-
dances not requiring treatment increased). Then, after this period
of reduction, STI rates overall, and notably those for gonorrhoea,
syphilis and viral STIs, began to increase from 1995 [15].
Increases in sexual risk behaviours have also been described [16].
Hence, we would expect there to have been increased exposure to
C. trachomatis in women becoming sexually-active (i.e. reaching
around 17–18 years of age) from 1993 onwards. Screening of
asymptomatic individuals for chlamydia has increased markedly in
recent years, particularly since the National Chlamydia Screening
Programme (NCSP) began to offer sexually active people under 25
years screening annually and on change of sexual partner in order
to detect infections in young people and reduce the prevalence of
infection and incidence of sequelae [17–19]. In 2007/08, around
300,000 tests were conducted via the NCSP, increasing to 1.4
million by 2010/11. Tests in all settings (including Genitourinary
medicine (GUM) clinics) in 2010/11 summed to over 2.1 million,
with approximately 43% of young women and 22% of young men
tested (on the assumption that each test represents an individual)
[20]. The impact of widespread, opportunistic screening, as
practised in England, on chlamydia epidemiology has not been
empirically established.
We report the results of the first population-based study of
antibodies to the C. trachomatis-specific antigen Pgp3 in England
using the recently developed and validated Pgp3 ELISA and a
population-based serum collection from 17–24 year old women.
This assay performs significantly better in women than men with a
sensitivity of 44.2% in latter [10]. We explore two expected
epidemiological variations: increased (cumulative) infection with
age, up to 25 years, and the increased infection rates over time
from the mid-1990s to early 2000s that have been described by
others [15]. We then explore seroprevalence changes in more
recent years.
Methods
Serum specimens were obtained from Public Health England’s
Sero-Epidemiology Unit collection. This consists of unlinked
residual sera submitted to laboratories in England for routine
microbiological or biochemical investigations. Sera from individ-
uals known to be immuno-compromised and repeat sera from the
same individuals were excluded [21,22]. In addition, we excluded
any sera known to have been collected at a GUM clinic. A small
number of selected specimens (0.3%) were of insufficient volume
for testing.
Sera from 4,732 women aged 17–24 years came from twenty-
nine laboratories in eight regions of England that had collected
samples between 1993 and 2010. The sample was chosen
pragmatically, with numbers limited by available sera and
competing needs for use of these sera. Between 1993 and 2002
samples were taken at 3-yearly intervals spanning the years of
putative increases in chlamydia transmission. The choice of every
3rd year was judged sufficient to capture trends over time and also
captured the aging of 2-year birth cohorts. We did not sample
from 2003–2006 because collected sera numbers were low during
the mid-2000s. From the more recent years, 2007 to 2010, samples
were taken from each year to maximise data for trend analyses
over this shorter period. The age-groups 17–18, 20–21 and 23–24
were sampled from every collection year to enable analysis by
these age groups across the whole period. From 2007 onwards, 19
and 22 year olds were also sampled to give a full range by year of
age for this recent period. As seroprevelance is lower at younger
ages (less cumulative incidence) under 17 year olds were not
included as testing these ages was considered less efficient in
generating information about trends over time, given seropreva-
lence is a tool for cumulative infection, not incident infection (in
contrast to NAAT data). This sampling frame and the numbers by
year and age were determined as likely to maximise the precision
of trends by age and time up to 2002 and of age-standardised
prevalence for 17–24 year olds from 2007 to 2010, given the
numbers of stored sera available.
Samples were tested for C. trachomatis Pgp3 antibody at Imperial
College London using the indirect Pgp3 assay described previously
[10]. Briefly, a Maxisorp 96-well microtitration plate (Nunc, DK)
was coated with 100 ng/well of the Pgp3 protein and blocked with
1% Hammersten casein in PBS-Tween-20 (blocking buffer).
Antisera were assayed at a dilution of 1:100 in blocking buffer,
secondary antibody added, then TMB substrate. The reaction was
allowed to develop and absorbance read at 450 nm. Sera were
considered to be seropositive at the 0.473 cut-off, determined using
ROC curve analysis with 356 C. trachomatis-positive sera and 722
paediatric (C. trachomatis-negative) sera [10]. We repeated the assay
on a random selection of 80 C. trachomatis Pgp3 antibody-negative
paediatric control sera which were assayed in duplicate and the
mean determined. The mean absorbance value for this assay and
the original were compared by Student’s t-test and were not
significantly different (p.0.05).
Statistical Analyses
Crude seroprevalence was calculated by age group and year.
Age-standardised seroprevalence was calculated for the combined
age group data using direct standardisation. The population of
England in 2004 constituted the reference population [23].
Analyses for trends by increasing age were conducted within birth
cohorts, to reduce confounding by secular trends. Trends over
time or by birth cohort were examined using the score test for
trend. Analyses for trend over time were conducted separately for
data from 1993 to 2002 and for data from 2007 to 2010. All
analyses were carried out using STATA 12.0 (StataCorp. 2011.
Stata Statistical Software: Release 12. College Station, TX:
StataCorp LP).
The data are held by Public Health England and may be
obtained by contacting the author for correspondence.
Ethics Statement
National Research Ethics Service (NRES) approval was granted
by the Joint University College London/University College
London Hospital (UCL/UCLH) Committees on the Ethics of
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Human Research. (Research Ethics Committee number 05/
Q0505/45).
Results
We tested 1,314 women aged 17–18 years, 1,415 aged 20–21,
1,420 aged 23–24 and 583 aged 19 or 22 at the time their blood
sample was taken. Of the total 4,732 serum samples tested in our
indirect Pgp3 ELISA, 826 of them were antibody positive (17.5%).
Changes in Pgp3 Seroprevalence with Age within Birth
Cohorts
Increasing seroprevalence with age was seen: point estimates for
crude seroprevalence were higher in the older age groups within
each two-year birth cohort, as would be expected for a marker of
cumulative infection, apart from those born between 1989 and
1990 (Figure 1). However, the increases by age, from 17–24 years,
were small and trends by age within birth cohorts were not
statistically significant.
Changes in Pgp3 Seroprevalence between 1993 and
2002
Between 1993 and 2002, age-standardised seroprevalence
increased from 17% to 21% (p= 0.053) (Table 1 and Figure 2).
Seroprevalence increase over time during this period was seen in
all age groups, although none was statistically significant. Among
women turning 17 or 18 between 1993 and 1999 (i.e. born 1975–
82), age-specific seroprevalence increased over time (Figure 1).
Seroprevalence at age 17–18 increased from 12% in 1993 to 17%
in 1996, and to 18% in 1999 (p = 0.078). Seroprevalence at age
20–21 increased from 12% in 1996 to 18% in 1999 and to 22% in
2002 (p = 0.025), while seroprevalence at age 23–24 increased
from 18% in 1999 to 24% in 2002 (p = 0.15).
The pattern of seroprevalence by age and over time between
1993 and 2002 was, therefore, broadly reflecting the epidemio-
logical variations we expected to see.
Changes in Pgp3 Seroprevalence from 2007–2010
For the more recent period, between 2007 and 2010, age-
standardised seroprevalence among the combined age groups (17–
24 years) decreased from 20% (95% CI 17%–23%) to 15%
(95%CI 12%–17%) (p = 0.0001) (Table 1). The biggest fall was
observed among 20 to 21 year olds, where seroprevalence more
than halved from 21% in 2007 to 9% in 2010 (p = 0.002) (Table 1
and Figure 2). The decline among 17–18 year olds was smaller
(from 11% to 9%) and not statistically significant (p = 0.27). There
was no consistent trend in seroprevalence among 23–24 year olds
between 2007 and 2010.
Discussion
Based on our sample, chlamydia Pgp3 antibody prevalence
increased non-significantly, but consistently, by birth cohort in
women reaching 17 between 1993 and 2000, in 17–24 year olds
over time between 1993 and 2002, and within birth cohorts by age
(with the exception of those born 1972–1973). This is consistent
with expectations based on other epidemiological information.
Chlamydia seroprevalence then declined steadily in young women
under 24 years of age between 2007 and 2010, the greatest
reduction being observed in 20–21 year olds. Our findings suggest
Figure 1. Cumulative C. trachomatis seroprevalence by birth cohort within three age groups. Missing bars occur where years of birth were
not represented in the samples (selected by age and year of collection).
doi:10.1371/journal.pone.0072001.g001
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that exposure to infection, or at least to antibody-inducing
infection, may have declined in recent years.
The population tested in the survey consists of individuals
accessing healthcare in England with collection of blood samples
for diagnostic or screening purposes. Previous studies using the
same collection have found the sample source is broadly
representative of the general population, at least for relatively
common infections. Although we can not know whether individ-
uals tested in this study are of higher or lower risk of STIs than the
general population, this sample source has been used informatively
for another STI, namely HPV [24]. Neither do we have
information on changes in selection bias in our sample source
over time. The study was restricted to, and somewhat limited by,
the available numbers of sera by age and year. The Pgp3 antibody
ELISA sensitivity and specificity has been rigorously defined using
characterised sera from 164 women known to have been infected
and 722 chlamydia-negative children aged 2–13 years [10]. We
have also extended this analysis and observed that Pgp3 antibody
decreases in the first 6 months following infection then plateaus
and that chlamydia antibody is more readily detectable in women
Table 1. Seroprevalence of C. trachomatis antibody by age group and year of sample collection.
Age group (years)
Year of
collection Tested Positive Prevalence (%) 95% CI
P-value for
trenda
17–18 1993 200 24 12 7 217 1993–2002
1996 123 21 17 10 224
1999 201 37 18 13 224 0.110
2002 199 35 18 12 223
2007 104 11 11 5 217 2007–2010
2008 143 19 13 8 219
2009 140 9 6 2 211 0.268
2010 204 18 9 5 213
20–21 1993 200 38 19 14 224 1993–2002
1996 142 17 12 7 217
1999 200 36 18 13 223 0.330
2002 200 43 22 16 227
2007 193 41 21 15 227 2007–2010
2008 156 28 18 12 224
2009 140 23 16 10 223 0.002
2010 184 17 9 5 213
23–24 1993 199 39 20 14 225 1993–2002
1996 150 31 21 14 227
1999 199 36 18 13 223 0.402
2002 200 48 24 18 230
2007 192 50 26 20 232 2007–2010
2008 152 33 22 15 228
2009 140 25 18 11 224 0.572
2010 188 46 24 18 231
Age groups combinedb,c 1993 599 101 17 14 220 1993–2002
1996 415 69 17 13 220
1999 600 109 18 15 221 0.053
2002 599 126 21 18 224
2007 489 102 19 16 223 2007–2010
2008 451 80 18 14 221
2009 420 57 14 10 217 0.001
2010 576 81 14 12 217
All years of age, 17 to 24c 2007 635 135 20 17 223 2007–2010
2008 618 111 18 15 221
2009 560 73 13 10 216 0.0001
2010 706 102 15 12 217
aScore test for trend.
b17–18 year olds, 20–21 year olds and 23–24 year olds combined. For continuity of data in this table, and because they are not very meaningful as single-year age
groups, we do not show the data for 19 and 22 year olds.
cPrevalence age standardised to ONS 2004 population.
doi:10.1371/journal.pone.0072001.t001
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with multiple episodes of infection [12]. Prospective population-
based studies would be desirable to enable more accurate
characterisation of how Pgp3 antibody changes with time since
infection.
The seroprevalence at age 17–18 was high. A nationally-
representative survey of sexual behaviour in 2000 found that 50%
of women reported sexual debut by age 17 [25]. The median age
of first sexual intercourse reported by the Health Survey for
England in 2010 was 17 [26]. We would need to consider partner
change rates and chlamydia transmission rates, as well as
likelihood of very recent infection and therefore higher seroprev-
alence (before any waning) to investigate whether the level of
seroprevalence we found is fully consistent with knowledge about
sexual exposure to chlamydia. The seroprevalence unfailingly
exceeded the proportion of women found to be infected by
NAATs in other studies [1,3] and of women who had undergone
chlamydia screening in recent years [4], as expected for a
cumulative and specific marker of infection. This relative
magnitude is as we would expect. Unlike most surveys of
chlamydia infection that require genital samples, our population
was not restricted to sexually active women.
The lack of a strong and steady increase in seroprevalence by
age from 17 to 24 years within birth cohorts suggests that
seroprevalence is not an absolute marker of all past chlamydia
infection. Such a marker would be expected to rise with increasing
numbers of sexual partners in this group. However, there are other
possible explanations for this. The population tested in the survey
may differ by age in terms of how well they represent their age
cohort with respect to chlamydia infection. Reasons for blood
testing do vary by age and some of these reasons may be associated
with sexual behaviour e.g. antenatal testing. As this was an
anonymous study, we were unable to explore these selection biases
further, neither were we able to explore the relationship between
seropositivity, symptoms and treatment among the women tested.
Another possible anomaly was a large drop in seroprevelance
amongst 17–18 year olds between 2002 and 2007. This may
simply be a sample size issue as the confidence limits overlap.
Women aged 20–21 in 1993 had a high seroprevalence, relative
to this age in later years. These women would have turned 17 in
1990 and earlier. This suggests that chlamydia infection in young
people continued to fall through the late 1980s and early 1990s,
possibly as a result of safer sexual practices [15,27]. There has
been only one previous study looking at chlamydia seroprevalence
in a population based study in Europe; Lyytikainen et al. studied C.
trachomatis seroprevalence in a subcohort of 8000 women stratified
by calendar years (1983–1989, 1990–1996, 1997–2003) and age at
time of sample, from a Finnish population serum bank.
Participants were women under 29 yrs, having at least two
pregnancies [28]. The study assessed prevalence of past exposure
to genital C. trachomatis, using Anilabsystems MOMP peptide
ELISA, and explored changes over time by comparing age-specific
prevalence at different time-points. Unlike our observations, a
declining prevalence of C. trachomatis antibody was observed from
1983 to1989 and 1997–2003 [28]. The authors postulated that this
may be due to more intensive testing and possible earlier diagnosis,
resulting in poorer humoral responses, i.e. fewer antibody-
Figure 2. Seroprevalence of C. trachomatis antibody by age group and year of sample collection. (For continuity of data in this table, and
because they are not very meaningful as single-year age groups, we do not show the data for 19 and 22 year olds).
doi:10.1371/journal.pone.0072001.g002
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inducing infections in these women. However, bias in the sample
selected (2 pregnancies required for inclusion), uncertainties with
the methodological analysis and changes in fertility patterns over
the 20 years of the study which may have altered the
characteristics of those having children under the age of 30 [29]
may also have contributed. In addition, the Anilabsystems MOMP
peptide ELISA is less sensitive than the pgp3 ELISA and repeat
infection does not result in a sustained greater persistence of
antibody compared to a single infection [10,12]. If age at first, and
only, infection had decreased, we might expect a reduction in age-
specific seroprevalence, as seroprevalence decreases with time
since infection [12]. This seems an unlikely explanation of our
findings, as earlier age of sexual activity is more likely to be
associated with an ongoing higher risk of infection.
The decline in seroprevalence during the recent period, 2007–
2010 is striking (Table 1 and Figure 2). During this time period,
substantial efforts have been directed to increase screening of
young sexually active people for chlamydia, resulting in an
increase from 1.3 million tests in 2008 to 2.1 million tests in 2011
[20]. Screening seeks to reduce the number of infections,
progression to disease and duration of infection and one would,
therefore, expect seroprevalence to fall if screening was effective,
whatever the balance of incidence, re-infection and frequency and
timing of treatment in determining seroprevalence. For example, if
treatment prevents the development of antibody, seroprevalence
could fall without screening necessarily being effective at reducing
transmission in the population. Mathematical modelling suggests
that the levels of screening uptake achieved in England should
have reduced population prevalence [30]. Other aspects of the
National Sexual Health Strategy introduced in England in 2001,
which also encouraged safer sexual practices, including condom
usage and rapid access to treatment for symptomatic individuals,
may also have been influential [18]. Although the likelihood of
seropositivity is not equal for all infections [12–14] the extent to
which seroprevalence is a measure of antibody-inducing infection
may make it a more interesting observation in relation to
chlamydia control than a measure of prevalence alone, particu-
larly if early treatment of asymptomatic infection reduces both
seroconversion and risk of chronic sequelae [14,31].
Seroprevalence for Pgp3 offers an additional viewpoint on the
epidemiology of chlamydia in England, and a rare view of the risk
of chlamydia infection (at least, antibody-inducing infection) in
female subjects who are not indirectly selected via specimen type
for their known sexual activity. Our data suggest that there is
already a substantial risk of chlamydia infection in girls in England
by the age of 17, which supports the introduction of annual
screening of sexually active girls at a young age.
This study demonstrates that seroprevalence has the potential to
be an important new tool for improving our understanding of
chlamydia epidemiology and to contribute to evaluation of
chlamydia control. One advantage of this tool is it enables the
use of opportunistic collections of sera that do not suffer from the
costs and participation biases typical of studies requiring collection
of genital samples for DNA testing. Screening of asymptomatic
young people is recommended in a number of other countries,
including the USA (sexually active young females) [32] and
evaluation tools are clearly needed to measuring the impact of this
activity [19,32].
The likelihood that diagnosis (and treatment) by screening
reduces serocoversion, and that antibody levels wane over time
and are boosted by repeat infections are complications to the use
of these data to estimate age-specific infection rates, increasingly so
with increasing age. Analyses of antibody titres may give some
insight into these aspects, and are one area for further work. We
have observed that Pgp3 antibody decreases in the first six months
following infection then reaches a plateau and that chlamydia
antibody is more often detected following multiple episodes of
infection [12]. Further investigation of the natural history of
antibody responses is, therefore, warranted, ideally via prospective
studies that can show changes with time since infection. Serology
should be explored further as a tool for evaluation of chlamydia
control, including chlamydia screening programmes.
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